Sign Out
Pregnancy: Methimazole (the metabolite of Carbimazole) has been the anti-thyroid drug most frequently involved in the few reports of congenital defects following maternal use of such drugs. Infants exposed to Methimazole have been born with scalp defects (aplasia cutis congenita). Other effects include choanal atresia (an upper respiratory tract defect), esophageal atresia and tracheoesophageal fistula.
Lactation: Safety of breastfeeding during maternal treatment depends partly on the amount of Methimazole distributed into breast milk. Neonatal development and thyroid function of the infant should be closely monitored and the lowest effective dose used.
